Aug 2026· Journal of Cellular Biochemistry· Vol 127 8, pp.
e70114
· 0 citations· 97 references
Medicine
TL;DR
The complex function of ALKBH5 in kidney diseases and its underlying mechanisms are reviewed, its potential as a therapeutic target is explored, its therapeutic potential is evaluated, and the need for cell- and pathology-specific strategies to enable precise intervention is highlighted.
Abstract
ALKBH5, as an m6A demethylase, plays a crucial regulatory role in various kidney diseases such as acute kidney injury, chronic kidney disease, renal fibrosis and renal cell carcinoma. However, its function often exhibits contradictory effects: In renal fibrosis, ALKBH5 has been reported to both promote and suppress fibrogenesis, whereas in renal cell carcinoma most studies support an oncogenic role, but some clinical observations link ALKBH5 downregulation to poor prognosis. These contradictions may stem from differences in cell types, disease stages, and microenvironments. This manuscript systematically reviews the complex function of ALKBH5 in kidney diseases and its underlying mechanisms, explores its potential as a therapeutic target, evaluates its therapeutic potential, and highlights the need for cell- and pathology-specific strategies to enable precise intervention. Future research should focus on its cell and pathological background specificity to achieve precise intervention.
CD38 is a highly conserved multifunctional enzyme that regulates intracellular calcium signaling and NAD⁺ metabolism. Although extensively studied in cancer and autoimmune diseases, growing evidence points to a critical role for CD38 in both normal and diseased liver physiology. In hepatic tissue, CD38 is expressed on...
J. Eng, Blake R. Peterson, Sylvester M. Black· Annals of Hepatology· 0 citations
A spatiotemporal framework is proposed that extends beyond previous disease- or pathway-centered perspectives by integrating the timing and cellular context of S100A8/A9 signaling to establish stage-specific biomarker and therapeutic strategies targeting S100A8/A9 in precision nephrology.
Meng-Ge Zhu, Meng-Dan Lu, Jia-Wei Cao et al.· Journal of Inflammation Rese...· 0 citations
MicroRNA-21 (miR-21) has long been regarded as one of the most promising molecular targets in chronic kidney disease (CKD) because of its consistent upregulation across diverse renal disorders and its involvement in fibrosis, inflammation, oxidative stress, and metabolic dysfunction. Strong preclinical evidence demonst...
V. Popović, Aleksandar Sič, Selena Gajić et al.· Medical Science· 0 citations
This review examines emerging mechanisms that govern kidney fibrogenesis, with emphasis on therapeutic tractability, and considers how experimental models can improve target prioritization and drug development, and summarizes repurposed drugs, pathway-targeted agents, receptor-directed strategies and cell-based approac...
Kidney disorders have become a prevalent global public health crisis, accompanied by soaring morbidity and insufficient therapeutic regimens in clinical practice. Celastrol, a biologically active pentacyclic triterpenoid isolated from
Tripterygium wilfordii
, is well documented to exert powerful anti-inflammatory,...
Yi-Ning Chen, Meng-Dan Lu, Ting Xu et al.· Asian Pacific Journal of Tro...· 0 citations
Chronic kidney disease (CKD) has become a global public health issue, with progressive kidney fibrosis serving as a key pathological process leading to kidney failure, and current therapeutic approaches remain largely ineffective in reversing this progression. SIRT1, as an NAD⁺-dependent deacetylase, plays a central pr...
Yu-Cheng Han, Qian-Wei Wang, Xuan-Bing Pan et al.· Frontiers in Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
